Home Tags China

Tag: China

Exclusive ADC-focused and Oncology deals in China Account for 41% of...

Over the past five years China has emerged as a major force in the research and development of innovative therapies for the treatment of...

Gearing Up to be In the Center of ADC Development

Following intensified investments, new partnerships, out-licensing ADC assets, and major scientific advances from companies including Bristol Myers Squibb (a US $8.4 billion deal with SystImmune), AstraZeneca (the company signed a US $ 600 million dollar deal to obtain global from LaNova Medicines for pre-clinical ADC candidates), Roche, Lonza, MilliporeSigma, BioNTech (acquired 2 different ADC assets from DualityBio for an upfront payment of US $170 million. The company also obtained a novel ADC HER3 assets from MediLink Therapeutics), Myricx Bio (licensed rights to an antibody discovered by WuXi Biologics),  while GlaxoSmithKline (acquired ex-China rights for B7-H4 ADC from Hansoh Pharma in a $1.57 billion deal, plus royalties on sales), and others, China is expected to drive the next research boom in novel, innovative medicines, like antibody-drug conjugates (ADC).

Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

WuXi XDC and AbTis to Collaborate in the Development and Manufacturing...

Chinese WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, a Contract Research, Development and Manufacturing Organization focusing on end-to-end bioconjugates services, and...

Sacituzumab Govitecan Approved in China for Second-Line Metastatic Triple-Negative Breast Cancer

China's National Medical Products Administration (NMPA) has approved sacituzumab govitecan (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic...

Anti-Nectin-4 ADC Drug Receives IND Approval; Phase I Studies Started

The Center for Drug Evaluation (CDE) of China National Medical Products Administration has approved the investigational new drug application (IND) for 9MW2821, an anti-Nectin-4...

MabPlex awards CloudWorks4All with Enterprise Resource Planning (ERP) Contract

MabPlex USA, the North American subsidiary, China-based MabPlex (Yantai, Shandong Province, China) has contracted systems integrator CloudWorks4All, a leading life science and cloud ERP...

Real World-Ready

The stated aim of my old school is to make pupils ‘real world-ready’. This is a project conceived as one of boundless ambition in...

MabPlex Opens New Phase III and Commercial Manufacturing Facility

MabPlex International, a fully integrated Contract Development and Manufacturing Organization (CDMO) with sites in China and the United States, has inaugurated their new manufacturing...

Benefitting from the Worldwide Supply Chain in the development of Antibody-drug...

Timing is everything. Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and plagued with insufficient technical capacity...

X